Lusutrombopag (Mulpleta)
Thrombocytopenia in chronic liver disease
ApprovedCommercial
Key Facts
Indication
Thrombocytopenia in chronic liver disease
Phase
Approved
Status
Commercial
Company
About Nippon Shinyaku
Nippon Shinyaku's mission is to address high-unmet medical needs through pioneering science, particularly in rare diseases. Its key achievement is the development and commercialization of Viltepso (viltolarsen), an exon-skipping therapy for Duchenne muscular dystrophy, establishing its technological credibility. The company's strategy is built on deep R&D in targeted therapeutic areas, a dominant position in the Japanese market, and strategic international expansion, especially in the United States.
View full company profile